Developing a Clear Path Forward for Non–Clear-Cell Renal Carcinoma
Mené sur 35 patients atteints d'un carcinome rénal à cellules non claires de stade avancé (4 sous-types histologiques), cet essai de phase II évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité d'un traitement de première ligne combinant évérolimus et bévacizumab
The concept of combining vascular endothelial growth factor (VEGF) –directed and mammalian target of rapamycin (mTOR) –directed therapies is not new in the context of metastatic renal cell carcinoma (RCC). Two single-arm phase II trials of bevacizumab paired with everolimus showed modest activity and were followed by a randomized phase II experience that compared this regimen against bevacizumab with interferon-
α 2a
.
This randomized study failed to demonstrate a difference in clinical outcomes, which diminished enthusiasm for this treatment approach.
..
Journal of Clinical Oncology , éditorial en libre accès, 2016